Encision's Losses Mount Amid Revenue Decline, Raising Going Concern Doubts

TL;DR

**ECIA is bleeding cash and revenue, making it a high-risk bet unless they secure a major cash infusion ASAP.**

AI Summary

ENCISION INC. (ECIA) reported a significant increase in net loss for the three and six months ended September 30, 2025, alongside a decrease in total revenue. For the three months, net loss widened to $267,833 from $170,262 in the prior year, while total revenue declined by 13% to $1,528,050 from $1,755,388. The six-month period saw an even sharper increase in net loss, reaching $308,966 compared to $148,222 in 2024, with total revenue decreasing by 7.5% to $3,130,778 from $3,386,318. Product revenue, the primary driver, fell by 10.4% for the three months and 8.4% for the six months. Operating expenses decreased slightly by 3.2% for the three months and 2.5% for the six months, but this was insufficient to offset the revenue decline and increased operating loss. The company's cash position significantly decreased by $185,702 to $71,731 from March 31, 2025, raising substantial doubt about its ability to continue as a going concern beyond the first fiscal quarter of 2027 without additional financing. Shareholders' equity increased by $213,685 due to a $500,000 common stock issuance, partially offset by the net loss.

Why It Matters

This filing reveals a critical juncture for Encision Inc., as widening losses and declining revenue put its long-term viability at risk, directly impacting investors' capital. The 'going concern' warning signals potential insolvency, which could lead to a significant loss for shareholders if new financing isn't secured. For employees, this raises job security concerns, while customers might face uncertainty regarding product availability and support from a struggling medical device provider. In the broader market, this highlights the challenges faced by smaller medical device companies in a competitive landscape, especially those reliant on specific patented technologies like AEM, underscoring the importance of sustained innovation and market penetration.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt as to whether existing cash resources are sufficient to enable the Company to continue its operations for the next 12 months as a going concern" and that cash resources will only provide funding "into the first fiscal quarter of 2027." This is compounded by a net loss of $308,966 for the six months ended September 30, 2025, and a significant cash decrease of $185,702 during the same period, leaving only $71,731 in cash.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the explicit 'going concern' warning and declining financials indicate a high probability of further share price erosion or even bankruptcy without successful, immediate financing. New investors should avoid ECIA until a clear and secured funding plan is announced and executed.

Financial Highlights

debt To Equity

1.17

revenue

$1,528,050

operating Margin

-16.9%

total Assets

$4,056,759

total Debt

$2,191,972

net Income

-$267,833

eps

N/A

gross Margin

45.6%

cash Position

$71,731

revenue Growth

-13.0%

Revenue Breakdown

Key Numbers

• $267,833 — Net Loss (3 months) (Increased from $170,262 in prior year, indicating worsening profitability.)
• $308,966 — Net Loss (6 months) (Increased from $148,222 in prior year, highlighting a significant decline in financial performance.)
• $1,528,050 — Total Revenue (3 months) (Decreased by 13% from $1,755,388 in prior year, showing reduced sales.)
• $3,130,778 — Total Revenue (6 months) (Decreased by 7.5% from $3,386,318 in prior year, reflecting a sustained revenue downturn.)
• $71,731 — Cash Balance (Significant decrease from $257,433 at March 31, 2025, raising liquidity concerns.)
• $1,375,301 — Working Capital (Increased by $338,451 from March 31, 2025, primarily due to common stock issuance.)
• $500,000 — Proceeds from Common Stock Issuance (Helped increase shareholders' equity despite net loss, but not enough to offset cash burn.)
• 16,879,645 — Common Stock Shares Outstanding (Increased from 11,879,645 at March 31, 2025, indicating dilution.)
• $23,074,211 — Accumulated Deficit (Increased from $22,765,245 at March 31, 2025, reflecting ongoing losses.)
• 2027 Q1 — Cash Funding Horizon (Management estimates cash resources will only last until the first fiscal quarter of 2027.)

Key Players & Entities

• ENCISION INC. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• AEM (company) — Active Electrode Monitoring surgical instrument technology
• $267,833 (dollar_amount) — net loss for three months ended September 30, 2025
• $170,262 (dollar_amount) — net loss for three months ended September 30, 2024
• $308,966 (dollar_amount) — net loss for six months ended September 30, 2025
• $148,222 (dollar_amount) — net loss for six months ended September 30, 2024
• $1,528,050 (dollar_amount) — total revenue for three months ended September 30, 2025
• $3,130,778 (dollar_amount) — total revenue for six months ended September 30, 2025
• $71,731 (dollar_amount) — cash balance at September 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's cash balance significantly decreased to $71,731 as of September 30, 2025, from $257,433 on March 31, 2025. Management estimates cash resources will only last until Q1 2027, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Deteriorating Profitability [high — financial]: Net loss for the three months ended September 30, 2025, widened to $267,833 from $170,262 in the prior year. The six-month net loss also increased significantly to $308,966 from $148,222, indicating worsening financial performance.
• Declining Revenue [high — market]: Total revenue decreased by 13% for the three months ($1,528,050 vs $1,755,388) and 7.5% for the six months ($3,130,778 vs $3,386,318) ended September 30, 2025. Product revenue, the main contributor, fell by 10.4% and 8.4% respectively.
• Increased Operating Loss [medium — financial]: Despite a slight decrease in total operating expenses (3.2% for 3 months, 2.5% for 6 months), the decline in revenue led to an increased operating loss of $258,491 for the three months and $278,272 for the six months.
• Shareholder Dilution [medium — financial]: The company issued 5,000,000 common stock shares between March 31, 2025, and September 30, 2025, increasing shares outstanding from 11,879,645 to 16,879,645. This dilution, while raising capital, impacts existing shareholders.
• Increased Research and Development Expenses [medium — operational]: Research and development expenses increased by 30% for the three months ($201,392 vs $155,515) and 24.5% for the six months ($366,832 vs $294,695) ended September 30, 2025. While potentially strategic, this adds to the current financial strain.

Industry Context

Encision Inc. operates in a competitive medical device market, likely focusing on energy-based surgical devices. The industry is characterized by rapid technological advancements, stringent regulatory approvals (FDA), and significant R&D investment. Companies often face pressure to demonstrate clinical efficacy and cost-effectiveness to gain market adoption and reimbursement.

Regulatory Implications

As a medical device company, Encision Inc. is subject to rigorous regulatory oversight by bodies like the FDA. Changes in regulations, delays in product approvals, or recalls can significantly impact financial performance and market access. Compliance with evolving standards is critical and requires ongoing investment.

What Investors Should Do

1. Monitor cash burn and funding efforts
2. Analyze revenue recovery and product demand
3. Evaluate R&D investment strategy
4. Assess the impact of stock issuance

Key Dates

• 2025-09-30: End of Q2 Fiscal Year 2026 — Reporting period for the 10-Q, showing significant net loss increase and revenue decline.
• 2025-03-31: End of Q1 Fiscal Year 2026 — Previous balance sheet date, showing a higher cash balance of $257,433 and fewer shares outstanding.
• 2027-01-01: Estimated Cash Runway End — Management projects cash resources will be depleted by the first fiscal quarter of 2027, highlighting immediate funding needs.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company has historically incurred more losses than profits, reaching $23,074,211 as of September 30, 2025.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, necessitating disclosure of this risk.)

Operating loss

The loss a company incurs from its normal business operations before accounting for interest and taxes. (The company reported an operating loss of $258,491 for the three months and $278,272 for the six months ended September 30, 2025, driven by declining revenues.)

Common stock shares outstanding

The total number of shares of common stock that have been issued by a company and are held by investors. (Increased significantly from 11,879,645 to 16,879,645, indicating dilution due to stock issuance.)

Right of use asset

An asset representing a lessee's right to use an underlying asset for the lease term under a lease agreement, recognized under ASC 842. (Increased significantly from $568,395 to $1,116,454, likely due to new lease agreements or changes in lease accounting.)

Year-Over-Year Comparison

Compared to the prior year's periods ended September 30, 2024, Encision Inc. (ECIA) has experienced a significant downturn. Total revenue for the three months fell by 13.0% to $1,528,050, and for the six months by 7.5% to $3,130,778. This revenue decline, coupled with increased R&D spending, has led to a substantial widening of the net loss, from $170,262 to $267,833 for the three-month period and from $148,222 to $308,966 for the six-month period. The company's cash position has also deteriorated sharply, raising going concern issues.

Filing Documents

• ecia_10q.htm (10-Q) — 526KB
• ex10x13.htm (EX-10) — 24KB
• ex10x14.htm (EX-10) — 53KB
• ex31x1.htm (EX-31.1) — 11KB
• ex31x2.htm (EX-31.2) — 11KB
• ex32x1.htm (EX-32.1) — 7KB
• 0001079973-25-001709.txt ( ) — 3465KB
• ecia-20250930.xsd (EX-101.SCH) — 19KB
• ecia-20250930_cal.xml (EX-101.CAL) — 38KB
• ecia-20250930_def.xml (EX-101.DEF) — 70KB
• ecia-20250930_lab.xml (EX-101.LAB) — 216KB
• ecia-20250930_pre.xml (EX-101.PRE) — 179KB
• ecia_10q_htm.xml (XML) — 498KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 11 ITEM 3 -

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 17 ITEM 4 -

Controls and Procedures

Controls and Procedures 18 PART II. OTHER INFORMATION 19 ITEM 1 -

Legal Proceedings

Legal Proceedings 19 ITEM 1A -

Risk Factors

Risk Factors 19 ITEM 2 - Unregistered Sales of Equity Securities and Use of Proceeds 19 ITEM 3 - Defaults Upon Senior Securities 19 ITEM 4 - Mine Safety Disclosures 19 ITEM 5 - Other Information 19 ITEM 6 - Exhibits 20

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION ITEM 1 - Condensed Interim Financial Statements Encision Inc. Condensed Balance Sheets September 30, 2025 Unaudited March 31, 2025 Audited ASSETS Current assets: Cash $ 71,731 $ 257,433 Accounts receivable 761,947 786,471 Inventories 1,468,863 1,483,182 Prepaid expenses 144,331 85,679 Total current assets 2,446,872 2,612,765 Equipment: Furniture, fixtures and equipment, at cost 2,628,661 2,585,446 Accumulated depreciation ( 2,378,645 ) ( 2,340,689 ) Equipment, net 250,016 244,757 Right of use asset 1,116,454 568,395 Patents, net 161,427 171,890 Other assets 81,990 72,892 TOTAL ASSETS $ 4,056,759 $ 3,670,699 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 314,815 $ 346,900 Line of credit 31,706 395,964 Secured notes 35,202 44,128 Accrued compensation 199,657 180,850 Deferred Revenue — 17,401 Other accrued liabilities 147,019 160,274 Accrued lease liability 343,172 430,398 Total current liabilities 1,071,571 1,575,915 Long-term liabilities: Secured notes 162,249 177,470 Accrued lease liability 958,152 266,212 Total liabilities 2,191,972 2,019,597 Commitments and contingencies (Note 4) — Shareholders' equity: Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding — — Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 16,879,645 and 11,879,645 issued and outstanding at September 30, 2025, and March 31, 2025, respectively 24,938,998 24,416,347 Accumulated (deficit) ( 23,074,211 ) ( 22,765,245 ) Total shareholders' equity 1,864,787 1,651,102 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 4,056,759 $ 3,670,699 The accompanying notes to financial statements are an integral part of these unaudited condensed financial statements. 1 Encision Inc. Condensed Statements of Operations (Unaudited) Three Mont

View Full Filing

View this 10-Q filing on SEC EDGAR